Lv2
160 积分 2023-10-31 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
1个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
2个月前
已完结
Development of a Scalable Plug-and-Play Platform for Dual-Targeting LPA and PCSK9, and Beyond, in Cardiovascular Disease Treatment
2个月前
已完结
Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects
3个月前
已完结
Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects
3个月前
已完结
Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals
4个月前
已完结
Implementing the commitments of the World Health Assembly kidney health resolution: a key opportunity to improve health for millions
4个月前
已关闭
Clinical Correlates of Ambulatory BP Monitoring among Patients with CKD
5个月前
已完结
Nocturnal Hypertension or Nondipping: Which Is Better Associated With the Cardiovascular Risk Profile?
5个月前
已完结
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
5个月前
已完结
皖公网安备34019202002308
